Sex: U
Vaccine: COVID19
Symptoms: Vaccination site swelling, Vomiting
Clinical narrative: Mild malaise/feeling sick and no interference with activity; Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch); Mild injection site redness; Mild injection site swelling; Moderate fever (101.3 to 102 °F); Moderate muscle pain with some interference with activity; Mild fatigue and no interference with activity; Joint pain and no interference with activity; Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting; Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting; Headache that interfered with activity OR required repeated use of a nonprescription pain reliever; This spontaneous case was reported by a non-health professional and describes the occurrence of MALAISE (Mild malaise/feeling sick and no interference with activity), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch)), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling) and PYREXIA (Moderate fever (101.3 to 102 °F)) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced MALAISE (Mild malaise/feeling sick and no interference with activity), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch)), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling), PYREXIA (Moderate fever (101.3 to 102 °F)), MYALGIA (Moderate muscle pain with some interference with activity), FATIGUE (Mild fatigue and no interference with activity), ARTHRALGIA (Joint pain and no interference with activity), NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting) and HEADACHE (Headache that interfered with activity OR required repeated use of a nonprescription pain reliever). At the time of the report, MALAISE (Mild malaise/feeling sick and no interference with activity), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch)), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling), PYREXIA (Moderate fever (101.3 to 102 °F)), MYALGIA (Moderate muscle pain with some interference with activity), FATIGUE (Mild fatigue and no interference with activity), ARTHRALGIA (Joint pain and no interference with activity), NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting) and HEADACHE (Headache that interfered with activity OR required repeated use of a nonprescription pain reliever) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In December 2023, Body temperature: 101.3 to 102 °F.         Subject ID was reported. Subject ID was reported.  Concomitant medications were not reported.  It was reported that the patient experienced the events anytime during the 2 days after the COVID-19 vaccination, which occurred Monday, Dec 18, 2023 and Tuesday, Dec 19, 2023.  No treatment information was provided.   This case was linked to US-MODERNATX, INC.-MOD-2024-756041 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756041:Same reporter